Psyence Biomedical Limited (PBM) Market Cap to Net Income

For the small biotech firm Psyence Biomedical Ltd. (PBM), strict DEA and WHO oversight combined with patent restrictions represent significant hurdles. Meanwhile, management is currently restructuring internal processes following the consolidation of assets in an effort to meet market expectations. This chart featuring the 1.00 metric visualizes the dynamics of a business facing legal uncertainties and costly research.

Psyence Biomedical Limited (PBM) Price to Earnings Ratio: for the period 02/21/2024 - 12/31/2024

Comprehensive metric breakdowns and analytics for Psyence Biomedical Limited (PBM)

- share price and expert price forecast:

Price Performance Chart pacificbayminerals.com|PBM - Price Target Chart

- market capitalization details:

Market Valuation Psyence Biomedical Ltd.|PBM - Total Company Value

- business book valuation details:

Net Assets per Share Psyence Biomedical|PBM - Company Net Assets|Market-to-Book Ratio pacificbayminerals.com|PBM - Company Total Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

PBM - Net Income|Expected Net Profit Psyence Biomedical Ltd.|PBM - P/E Multiple|Projected Price to Earnings Ratio Psyence Biomedical Ltd|PBM - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Psyence Biomedical Ltd.|PBM - Operating profit EBITDA|Net earnings per share for the last 12 months Psyence Biomedical|PBM - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months pacificbayminerals.com|PBM - Net earnings per share growth this year|Expected earnings per share trend next year Psyence Biomedical Ltd.

Comprehensive company analysis:PBM (pacificbayminerals.com)

The P/E ratio reflects the market value of one ruble of net profit, determining the extent of the premium paid for an asset. This metric discounts investors' future expectations regarding business growth rates. Analyzing the P/E chart for the company allows for the identification of overbought or undervalued stock levels. For Psyence Biomedical Ltd. (PBM), this indicator confirms the efficiency of its autonomous mining ecosystem. The closed-loop raw material enrichment cycle reduces operating expenses, directly impacting the final multiple.

Analysis of competing companies